Charles Sternberg, Associate Editor01.10.23
Schott has opened a new facility in Phoenix, Arizona, to expand the development and manufacturing of diagnostics and life science consumables.
Launching a fully integrated microfluidic foundry in the United States validates Schott’s global growth plan and increases production capabilities to help get these products to market faster and more efficiently.
The new, almost 40,000-square-foot facility, comprising of clean room, high volume manufacturing of microarrays and microfluidic devices, allows the company to onshore critical manufacturing supporting the U.S. Government’s renewed interest in reshoring and revitalizing American manufacturing to secure critical domestic supply chains.
At the grand opening event on January 9, 2023, speakers from Schott, state, and local government officials, and prominent members of the Phoenix biotech community highlighted the significance of Schott expanding in the U.S.
“The United States is one of our most important markets, and we are pleased to expand our R&D and production facilities in this region” said Dr. Heinz Kaiser, a member of Schott’s management board. “Enhancing our global footprint with a manufacturing base in Phoenix not only expands our reach, but also caters to the fast-growing and dynamic diagnostics market in North America. We are eager to build a unique pipeline for this market in the U.S.”
Phoenix, AZ will mark Schott’s third diagnostics location, with other centers of excellence located in Jena, Germany, and Melbourne, Australia. However, this will be the first location to place a special emphasis bioscience capabilities using high-density microarrays for diagnostic and life science research.
The facility has the potential to create 10 to 30 million parts for diagnostics consumables per year. Over the next few years, it will create 150 jobs in the greater Phoenix area, growing Schott Minifab’s employee base in Phoenix by 300 percent.
Launching a fully integrated microfluidic foundry in the United States validates Schott’s global growth plan and increases production capabilities to help get these products to market faster and more efficiently.
The new, almost 40,000-square-foot facility, comprising of clean room, high volume manufacturing of microarrays and microfluidic devices, allows the company to onshore critical manufacturing supporting the U.S. Government’s renewed interest in reshoring and revitalizing American manufacturing to secure critical domestic supply chains.
At the grand opening event on January 9, 2023, speakers from Schott, state, and local government officials, and prominent members of the Phoenix biotech community highlighted the significance of Schott expanding in the U.S.
“The United States is one of our most important markets, and we are pleased to expand our R&D and production facilities in this region” said Dr. Heinz Kaiser, a member of Schott’s management board. “Enhancing our global footprint with a manufacturing base in Phoenix not only expands our reach, but also caters to the fast-growing and dynamic diagnostics market in North America. We are eager to build a unique pipeline for this market in the U.S.”
Phoenix, AZ will mark Schott’s third diagnostics location, with other centers of excellence located in Jena, Germany, and Melbourne, Australia. However, this will be the first location to place a special emphasis bioscience capabilities using high-density microarrays for diagnostic and life science research.
The facility has the potential to create 10 to 30 million parts for diagnostics consumables per year. Over the next few years, it will create 150 jobs in the greater Phoenix area, growing Schott Minifab’s employee base in Phoenix by 300 percent.